A case-control study of patients with resistant schizophrenia after clozapine discontinuation [2]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 1, 2007, Pages 90-91

  Marchand, Julie ^a   Grignon, Sylvain ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ANAMNESIS; BLOOD DYSCRASIA; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE DURATION; DRUG WITHDRAWAL; EMERGENCY WARD; FISHER EXACT TEST; HOSPITALIZATION; HUMAN; INFORMED CONSENT; LENGTH OF STAY; LETTER; MYOCARDITIS; PRIORITY JOURNAL; PSYCHIATRIST; QUALITY OF LIFE INDEX; RANK SUM TEST; RATING SCALE; RISK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE ATTEMPT; WAIST CIRCUMFERENCE; WITHDRAWAL SYNDROME;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CLOZAPINE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 33846194959     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200702000-00019     Document Type: Letter

References (12)

1. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
2. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996;32:683-697.
3. Baker M, White T. Life after clozapine. Med Sci Law. 2004;44:217-221.
4. Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J Clin Psychiatry. 2005;66:534-538.
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
6. Kreyenbuhl J, Valenstein M, McCarthy JF, et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res. 2006;84:90-99.
7. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review andmeta-analysis. Lancet. 2003;361:1581-1589.
8. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
9. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247-251.
10. Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp Community Psychiatry. 1988;39:1172-1177.
11. Hogan TP, Awad AG, Eastwood R. A selfreport scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
12. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.